Board of the Pension Protection Fund Invests $971,000 in Royalty Pharma PLC (NASDAQ:RPRX)

Board of the Pension Protection Fund acquired a new position in shares of Royalty Pharma PLC (NASDAQ:RPRX - Free Report) in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm acquired 31,200 shares of the biopharmaceutical company's stock, valued at approximately $971,000. Royalty Pharma accounts for about 1.1% of Board of the Pension Protection Fund's portfolio, making the stock its 22nd largest holding.

Several other institutional investors have also made changes to their positions in the business. Allworth Financial LP raised its position in Royalty Pharma by 417.6% in the fourth quarter. Allworth Financial LP now owns 1,087 shares of the biopharmaceutical company's stock worth $28,000 after purchasing an additional 877 shares in the last quarter. Louisbourg Investments Inc. acquired a new stake in Royalty Pharma during the first quarter valued at approximately $28,000. MassMutual Private Wealth & Trust FSB grew its stake in shares of Royalty Pharma by 76.4% in the 1st quarter. MassMutual Private Wealth & Trust FSB now owns 956 shares of the biopharmaceutical company's stock valued at $30,000 after purchasing an additional 414 shares during the period. Riverview Trust Co raised its holdings in shares of Royalty Pharma by 3,953.3% in the 4th quarter. Riverview Trust Co now owns 1,216 shares of the biopharmaceutical company's stock worth $31,000 after buying an additional 1,186 shares in the last quarter. Finally, Rakuten Securities Inc. raised its holdings in shares of Royalty Pharma by 160.5% in the 4th quarter. Rakuten Securities Inc. now owns 1,628 shares of the biopharmaceutical company's stock worth $42,000 after buying an additional 1,003 shares in the last quarter. 54.35% of the stock is currently owned by institutional investors and hedge funds.

Royalty Pharma Price Performance

Shares of NASDAQ:RPRX traded up $0.60 during trading on Friday, reaching $35.87. The stock had a trading volume of 3,740,759 shares, compared to its average volume of 3,672,238. The stock has a market capitalization of $20.17 billion, a PE ratio of 19.39, a P/E/G ratio of 1.84 and a beta of 0.48. The company has a debt-to-equity ratio of 0.68, a current ratio of 1.56 and a quick ratio of 1.56. Royalty Pharma PLC has a 52 week low of $24.05 and a 52 week high of $36.36. The business's 50-day moving average price is $33.40 and its 200 day moving average price is $31.48.

Royalty Pharma (NASDAQ:RPRX - Get Free Report) last released its quarterly earnings results on Thursday, May 8th. The biopharmaceutical company reported $1.06 earnings per share for the quarter, beating analysts' consensus estimates of $0.99 by $0.07. Royalty Pharma had a return on equity of 24.71% and a net margin of 48.23%. The firm had revenue of $839.00 million during the quarter, compared to analysts' expectations of $724.69 million. As a group, equities analysts predict that Royalty Pharma PLC will post 4.49 earnings per share for the current year.

Royalty Pharma Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Tuesday, June 10th. Stockholders of record on Friday, May 16th were paid a $0.22 dividend. The ex-dividend date was Friday, May 16th. This represents a $0.88 dividend on an annualized basis and a dividend yield of 2.45%. Royalty Pharma's dividend payout ratio (DPR) is presently 47.57%.

Analyst Upgrades and Downgrades

A number of brokerages have weighed in on RPRX. Wall Street Zen upgraded Royalty Pharma from a "hold" rating to a "buy" rating in a research report on Saturday, June 21st. Citigroup reissued a "buy" rating on shares of Royalty Pharma in a report on Friday, March 28th. Finally, Morgan Stanley began coverage on shares of Royalty Pharma in a report on Friday, May 16th. They issued an "overweight" rating and a $51.00 target price on the stock. Four equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the company currently has an average rating of "Buy" and a consensus price target of $47.33.

Royalty Pharma Company Profile

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.